Published in Microvasc Res on February 20, 2010
Human endothelial progenitor cells. Cold Spring Harb Perspect Med (2012) 1.68
Endothelial progenitor cell: a blood cell by many other names may serve similar functions. J Mol Med (Berl) (2013) 1.16
Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy. Br J Cancer (2012) 1.07
Human endothelial stem/progenitor cells, angiogenic factors and vascular repair. J R Soc Interface (2010) 1.04
Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS One (2012) 0.97
The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis (2012) 0.96
On the clinical relevance of circulating endothelial cells and platelets in prostate cancer. Br J Cancer (2013) 0.92
Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect. Oncotarget (2015) 0.86
Biology and flow cytometry of proangiogenic hematopoietic progenitors cells. Cytometry A (2014) 0.84
Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor. Thorac Cancer (2014) 0.83
Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. Pediatr Blood Cancer (2011) 0.83
Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. Neoplasia (2011) 0.82
The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence. PLoS One (2013) 0.82
Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. J Cancer Res Clin Oncol (2012) 0.80
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients. Oncotarget (2016) 0.79
Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer. Br J Cancer (2014) 0.78
Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: A critical evaluation. Mol Clin Oncol (2016) 0.76
CD144, CD146 and VEGFR-2 properly identify circulating endothelial cell. Rev Bras Hematol Hemoter (2015) 0.75
Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome. Int J Colorectal Dis (2015) 0.75
Enumeration of circulating endothelial cell frequency as a diagnostic marker in aortic valve surgery - a flow cytometric approach. J Cardiothorac Surg (2017) 0.75
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer (2008) 2.45
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol (2008) 2.10
Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res (2009) 2.00
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood (2005) 1.80
Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost (2005) 1.73
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood (2006) 1.69
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol (2010) 1.63
Autologous peripheral blood stem cell transplantation for myocardial regeneration: a novel strategy for cell collection and surgical injection. Ann Thorac Surg (2004) 1.48
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast (2012) 1.39
Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. Plast Reconstr Surg (2017) 1.38
The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression. Cancer Res (2011) 1.37
Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res (2003) 1.23
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res (2009) 1.20
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res (2006) 1.18
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. Blood (2006) 1.17
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res (2011) 1.13
Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl Acad Sci U S A (2008) 1.13
Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res (2011) 1.12
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res (2009) 1.07
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. Blood (2004) 1.07
Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer. Cancer Res (2013) 1.05
Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol (2002) 1.04
Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast (2005) 1.02
Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets (2005) 1.02
The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer (2014) 1.02
Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol (2003) 1.01
Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res (2004) 1.00
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (2011) 1.00
Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis (2014) 1.00
The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J Pathol (2005) 0.97
Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today (2012) 0.95
On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent. J Clin Oncol (2006) 0.95
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer (2012) 0.94
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int (2007) 0.91
Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res (2011) 0.90
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One (2013) 0.89
Hepatocyte-conditioned medium sustains endothelial differentiation of human hematopoietic-endothelial progenitors. Hepatology (2007) 0.89
Miniaturized FISH for screening of onco-hematological malignancies. Biotechniques (2010) 0.88
Sex-related efficiency in NSG mouse engraftment. Blood (2010) 0.88
Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLoS One (2011) 0.88
Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest (2012) 0.87
Circulating perivascular progenitors: a target of PDGFR inhibition. Int J Cancer (2011) 0.86
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer Drugs (2009) 0.86
Circulating endothelial cells and circulating endothelial progenitors. Recent Results Cancer Res (2012) 0.85
Amelioration of glucose control mobilizes circulating pericyte progenitor cells in type 2 diabetic patients with microangiopathy. Exp Diabetes Res (2012) 0.85
Spontaneous cell fusion of acute leukemia cells and macrophages observed in cells with leukemic potential. Neoplasia (2012) 0.85
EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS One (2010) 0.85
Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. Eur J Haematol (2004) 0.84
Skeletal muscle differentiation potential of human adult bone marrow cells. Exp Cell Res (2004) 0.84
A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients. PLoS One (2014) 0.83
Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. Mod Pathol (2003) 0.82
Human haemato-endothelial precursors: cord blood CD34+ cells produce haemogenic endothelium. PLoS One (2012) 0.82
Stem cell plasticity: time for a reappraisal? Haematologica (2005) 0.82
SP4, a novel anti-cyclin D1 rabbit monoclonal antibody, is a highly sensitive probe for identifying mantle cell lymphomas bearing the t(11;14)(q13;q32) translocation. Appl Immunohistochem Mol Morphol (2005) 0.82
In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue. Exp Hematol (2002) 0.81
Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. Front Biosci (Schol Ed) (2009) 0.81
Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep (2016) 0.80
Circulating endothelial cell number and viability are reduced by exposure to high altitude. Endothelium (2008) 0.80
Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. Oncology (2010) 0.80
Lenalidomide for multiple myeloma. N Engl J Med (2012) 0.79
Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. Mod Pathol (2004) 0.79
Circulating endothelial cells as biomarkers for patients receiving bevacizumab. Lancet Oncol (2011) 0.79
Simultaneous characterization of progenitor cell compartments in adult human liver. Cytometry A (2010) 0.79
zeta-Crystallin is a bcl-2 mRNA binding protein involved in bcl-2 overexpression in T-cell acute lymphocytic leukemia. FASEB J (2010) 0.79
Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Haematol (2003) 0.79
Circulating endothelial progenitor cells. N Engl J Med (2005) 0.79
If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer (2010) 0.79
Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer. Clin Cancer Res (2004) 0.79
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. Br J Haematol (2004) 0.78
Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Hum Pathol (2003) 0.78
Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer. Cancer Biol Ther (2010) 0.78
Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. Br J Haematol (2003) 0.77
Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype. Br J Haematol (2008) 0.77
Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. Int J Cancer (2004) 0.77
Strategies to investigate circulating endothelial cells in cancer. Pathophysiol Haemost Thromb (2005) 0.76
Chimerism of the transplanted heart. N Engl J Med (2002) 0.75
Blood-based biomarkers for the optimization of anti-angiogenic therapies. Cancers (Basel) (2010) 0.75
Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34- human stem cells. Br J Haematol (2003) 0.75
Stroma cells: a novel target of herceptin activity. Clin Cancer Res (2003) 0.75
Stromal cell-derived factor-1α promotes endothelial colony forming cell migration through the Ca2+-dependent activation of the extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase/AKT pathways. Stem Cells Dev (2017) 0.75
Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Sci Rep (2016) 0.75
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. Leuk Res (2008) 0.75